Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $495.75M. Across the group, the median move over the past trading day is +0.59%. Price change over the past year runs from −52.3% to +4.1% across the middle 80 percent of the group, with a median of −38.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | −3.82% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% | Aug 27, 2026 |
| 4592.T | SanBio Company Limited | $495.75M | Small cap | −55.90% | Sep 14, 2026 |
| SVA.TO | Sernova Biotherapeutics Inc | $30.03M | Micro cap | −38.89% | Sep 10, 2026 |
| PSH0.DE | Sernova Biotherapeutics Inc | $26.97M | Micro cap | −46.78% | Sep 10, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.